This page contains a Flash digital edition of a book.
NICE Guideline (CG180) recommends anticoagulation therapy* – not aspirin monotherapy – for stroke prevention in patients with NVAF1


ELIQUIS® is the only NOAC that


demonstrated superior risk reduction in stroke / systemic embolism with signifi cantly less major bleeding vs. warfarin2


When choosing an anticoagulant for your patients with NVAF


One choice stands out


NICE = National Institute for Health and Care Excellence NOAC = Novel Oral Anticoagulant NVAF = Non-Valvular Atrial Fibrillation NYHA = New York Heart Association


* NICE Guideline (CG180) suggest anticoagulation may be with apixaban, dabigatran etexilate, rivaroxaban or a vitamin K antagonist. See guideline for further information and for full list of recommendations.1


Note: edoxaban is not included in these guidelines as it did not have EU marketing


authorisation at the time of publication. However, edoxaban and all other NOACs have received NICE technology appraisal fi nal guidance.4 ELIQUIS®


Information on prescribing and adverse events reporting can be found overleaf (apixaban): An oral, direct factor Xa inhibitor indicated for prevention of stroke and systemic embolism in adult patients with


non-valvular atrial fi brillation (NVAF), with one or more risk factors such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; and symptomatic heart failure (NYHA Class ≥II).3


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108